Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy

Helen Trottier1,2,3*, Marie-Hélène Mayrand2,4, Maria Luiza Baggio5, Lenice Galan5, Alex Ferenczy6, Luisa L. Villa5,7, Eduardo L. Franco1 and for the Ludwig-McGill Cohort Study Group

Abstract

Background: Parity is well established as a risk factor for cervical cancer. It is not clear, however, how pregnancy influences the natural history of HPV infection and cervical neoplasia. Our objective was to study the risk of HPV infection and cervical squamous intraepithelial lesions (SIL) after pregnancy.

Methods: We used the Ludwig-McGill cohort study which includes 2462 women recruited in Sao Paulo, Brazil in 1993–97 and followed for up to 10 years. Cellular specimens were collected every 4–6 months for Pap cytology and HPV detection and genotyping by a polymerase chain reaction protocol. Study nurses recorded pregnancy occurrence during follow-up. HPV and Pap results from pregnant women were available before and after, but not during pregnancy. The associations between pregnancy and post-partum HPV infection/SIL were studied using generalized estimating equation models with logistic link. Adjusted odds ratios (OR) were estimated with empirical adjustment for confounding.

Results: We recorded 122 women with a history of pregnancy during follow-up. Of these, 29 reintegrated the cohort study after delivery. No association between HPV and pregnancy was found. A single SIL case (high grade SIL) occurred post-partum. Likewise, there was no association between pregnancy and risk of low grade SIL or any-grade SIL at the next visit (adjusted OR = 0.84, 95% CI: 0.46–15.33) after controlling for confounders.

Conclusions: No associations were found between pregnancy and HPV or LSIL. The single observed case of HSIL post-partum was more than would be expected based on the rate of these abnormalities among non-pregnant women. As this association was found with only one case, caution is required in the interpretation of these results.

Keywords: Cervical neoplasia, Pregnancy, Human papillomaviruses (HPV)

Background

The central causal role of the so-called high oncogenic-risk (HR)-human papillomavirus (HPV) genotypes, such as HPV-16 in cervical carcinogenesis, has been established [1]. HPV is a necessary but not sufficient cause of virtually all cases of cervical cancer worldwide. HR-HPV infection also causes a substantial proportion of other anogenital neoplasms and oral squamous cell carcinomas [2]. HPV infections are one of the most common sexually transmitted conditions in the world although the vast majority are transient, with only a small proportion becoming persistent and leading the development of cervical cancer [3]. The fact that HPV infection does not always progress to neoplastic disease suggests that interpersonal variations in the immune system may play a role in the clearance of HPV infections and/or in their acquisition. Other viral or environmental factors may also play a role [4]. For example, parity is a well-established risk factor for cervical cancer [5]. It is not clear, however, exactly how pregnancy influences the natural history of human papillomavirus (HPV) infection and cervical neoplasia. To our knowledge, there is no prospective study of the risk conferred by pregnancy on both HPV infection and cervical intraepithelial neoplasia. The aim of this prospective study was to analyse...
the risk of HPV infection and cervical squamous intraepithelial lesion following pregnancy.

Method
Subject recruitment
The women included in this study were enrolled into the Ludwig-McGill cohort, a longitudinal investigation of the natural history of HPV infection and precursor lesions of cervical cancer. A detailed description of the design and methods of the study has been published previously [6]. Briefly, women attending a maternal and child health program catering to a low-income neighborhood in São Paulo (Brazil) were recruited between 1993 and 1997 and followed for up to 10 years. Women were eligible to participate if they: 1) were between 18 and 60 years of age, 2) were permanent residents of São Paulo, 3) were not currently pregnant and had no intention of becoming pregnant during the first year of follow-up, 4) had an intact uterus and no current referral for hysterectomy, 5) reported no use of vaginal medication in the previous 2 days and 6) had no reported treatment for cervical disease in the previous 6 months. Subjects gave a signed informed consent. The study protocol was approved by institutional ethical and research review boards of the participating institutions in Canada (McGill University Research and Ethics Board, Montreal) and in Brazil (Ludwig Institute for Cancer Research São Paulo Branch Institutional Review Board (IRB) and by the IRB of the Hospital e Maternidade Escola Vila Nova Cachoeirinha Dr Mario Altenfender, São Paulo).

The study enrolled 2528 women, corresponding to a 70 % response rate and subsequently, 66 ineligible women were excluded. Follow-up for the remaining 2462 women consisted of 1 visit every 4 months for the first year and 2 visits per year thereafter. Cervical specimens were taken for Pap cytology and HPV testing at every visit with a fixed-sampling area Accelon device. For the first 4 visits and for each annual visit thereafter, subjects answered a nurse-administered questionnaire designed to collect information on socio-demographic, lifestyle, sexual, reproductive and contraceptive characteristics. Pregnancy status was registered by study nurses along with date and procedures of visits, reasons of dropouts and reintegration, and other study-relevant incidents. Pregnant women were excluded from the study during pregnancy and offered to be reintegrated in the study after a minimum of 45 days following delivery, if there was no clinical impediment and if they consented. HPV and Pap results from pregnant women were available before and after, but not during pregnancy.

Cervical cells specimen
An Accelon biosampler (Medscand, Inc., Hollywood, Florida) was used to collect ecto- and endocervical samples for each visit and a Pap smear was prepared on a glass slide and fixed with 95 % ethanol. The sampler containing the residual exfoliated cells was immersed in a tube containing Tris-EDTA buffer (pH 7.4) and agitated to release the cells. The tubes containing cell suspensions were frozen until testing. Samples were then sent to the Ludwig Institute for storage and testing. Pap smears were sent to the study centre in Canada for cytology reading by one of the co-authors (AF). Cytology reports were based on the 1991 Bethesda system for cytological diagnoses [7]; the Pap smears were read ‘blinded’ to all other test results for the same sample and for the same woman and findings were classified as normal, atypical squamous cells of undetermined significance (ASCUS), atypical glandular cells of undetermined significance (AGUS), low grade squamous intraepithelial lesion (LSIL), or high grade squamous intraepithelial lesion (HSIL).

HPV DNA testing
The Accelon device containing ecto- and endocervical cells was placed in a tube containing Tris-EDTA buffer (pH 7.4). DNA was extracted, purified by spin column chromatography, and amplified by polymerase chain reaction (PCR), using the MY09/11 and PGMY protocols [8, 9] for detection of HPV DNA. Typing of amplified products was performed by dot-blot hybridization with individual oligonucleotide probes and by restriction fragment length polymorphism (RFLP) analysis. This method identified more than 40 HPV genital types. Amplified products that hybridized only with a generic probe and were unidentifiable in RFLP analysis were classified as positive for unknown types. The genotypes tested included high oncogenic risk (HR-) HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 82, and low oncogenic risk (LR-) HPV types 6, 11, 26, 32, 34, 40, 42, 44, 53, 54, 57, 61, 62, 67, 69, 70, 71, 72, 81, 83, 84 and 89 (unknown types considered LR-HPVs) [10, 11]. We included more than 30 type-specific positive controls in hybridization membranes to control for experimental variation between different membranes. DNA specimen quality was checked by amplification of a 268-bp human β–globin gene region [8]. Specimens were tested blindly and precautions were taken to prevent contamination. Samples that were negative for both HPV and β–globin were considered inadequate for analysis.

Statistical analysis
We explored the relationships between pregnancy and outcomes such as HPV infection and cervical squamous intraepithelial lesions (SIL) using generalized estimating equation (GEE) via a logistic regression link, which take into account the clustering within each individual caused by the repeated-measurements design. GEE models were
based on an exchangeable correlation pattern. We studied the association between pregnancy and the presence of HPV, LSIL and HSIL. Post-partum visits were compared to other usual visits for the presence of HPV or SIL. We explored the relationship between HPV infection and pregnancy by considering grouped HPV genotypes per their oncogenic potential (high-risk and low-risk as described above), per their phylogenetic relationship within the genus Alpha-papillomavirus (species 3, 5, 6, 7, 9, 10) [12] and grouped HPV per their general tropism for the cervix or the vagina [13]. HPV group 1 (benign) included HPV types 6, 11, 32, 40, 42, 44 (cervical and vaginal species 1, 8, 10); HPV group 2 included HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 82 (cervical species 5, 6, 7, 9, 11); and HPV group 3 included HPV types 57, 61, 71, 72, 62, 81, 83, 84, 89 (vaginal species 3, 4, 15).

We estimated crude and adjusted odd ratios (ORs) with respective 95 % confidence intervals (CI). For adjusted estimates, we controlled for empirical confounders using a 5 % change-in-estimate method (variables that changed the estimates by +/− 5 % were included in the model) considering the following variables: age at enrolment (linear), race (white, non-white), marital status (single, married, widowed, separated, unmarried but living with partner), income (quartiles of income), smoking (never, current, former), age at first sexual intercourse (<15, 16–17, 18–19, 20+), number of previous pregnancies (0–1, 2–3, 4–6, 7+), Pap testing before enrollment in the cohort (yes, no) and lifetime number of sexual partners (0–1, 2–3, 4+). For the analysis concerning the association between SIL and pregnancy, we also considered HPV status (negative, LR-HPV only, any HR-HPV) as a potential confounder or mediator.

Results
A total of 24,558 visits. The mean and median follow-up time were 5.1 (SD = 3.2 years) and 6.4 (inter-quartile range = 1.0-7.5) years, respectively. The mean age at enrolment was 32.7 years (SD = 8.8; median = 32, range: 18–59) and most women were white (64 %). We recorded 122 women with a history of pregnancy during follow-up. After giving birth, 29 (23.8%) women reentered the study. The mean time between visits for reintegration into the cohort was 3.9 years (SD = 1.6).

Table 1 describes the characteristics at baseline (enrolment) according to the pregnancy status in the course of follow-up. Women who became pregnant over the course of follow-up were younger than those in the remainder of the cohort. The distribution of other age-dependent variables also differed according to pregnancy outcomes, e.g., women who did not become pregnant were more likely to have a normal cytology result and to be HPV negative at baseline. Table 1 also provides baseline data for women who had a pregnancy but who did not reintegrated the cohort after pregnancy. Overall, women lost to follow-up after pregnancies were largely comparable to those who reintegrated into the cohort after giving birth.

Table 2 presents the crude and adjusted ORs for the association between pregnancy and post-partum HPV infection and SILs. Six of the post-pregnancy visits were HPV positive (20.7 %), whereas 3787 out of 23,735 (16.0 %) visits without an intervening pregnancy yielded the same finding. We found no evidence that pregnancy increased the risk of detecting HPV at the next visit post-partum irrespective of the categories used to group HPV genotypes (range of adjusted ORs: 0.80-1.86; none statistically significant). Table 2 also shows the association between pregnancy and cytological abnormalities. A single SIL case (an HSIL) occurred post-partum. Likewise, there was no association between pregnancy and LSIL or any-grade SIL at the next visit (adjusted OR = 0.84, 95 % CI: 0.46-15.33) after controlling for confounders. The single observed case of HSIL post-partum was more than would be expected based on the rate of these abnormalities among non-pregnant women even after accounting for multiple confounders (OR = 8.75, 95 % CI: 1.00-77.03).

Discussion
In this longitudinal study, we analysed the risk of HPV infection and cytological abnormality following pregnancy. No association was detected between pregnancy and LSIL, nor for post-partum HPV infection. Although, the single observed case of HSIL post-partum was more than would be expected based on the rate of these abnormalities among non-pregnant women, this association was found with only one case, which calls for caution in interpreting these findings.

There are plausible mechanisms whereby pregnancy may influence the natural history of HPV infection and progression to clinical lesions. Increased levels of estrogen or growth hormone associated with pregnancy such as human chorionic gonadotropin (hCG) may increase HPV molecular activity [14, 15]. Studies on condyloma acuminata and laryngeal recurrent respiratory papillomatosis have shown that these lesions increase in number and size during pregnancy [16]. Others suggested that a reduced humoral response to HPV may occur in pregnant women [17].

Our finding of no increased risk of HPV detection with pregnancy concurs with other reports [18–27]. Only a few showed a higher risk of HPV infection in pregnant women [28–30]. The higher risk of HPV infection in these studies could be explained by confounding variables related to sexual activity, as pregnancy and HPV infection are both acquired through sex. Some studies have shown a higher risk of HSIL with
pregnancy. Morimura et al. (2002) [31] have shown that the proportion of women with of abnormal Pap test results was significantly higher during pregnancy. Jensen and colleagues (2013) [32] found that childbirth increased the risk of HSIL, over and above the risk of persistent HPV infection. Taken together, those studies

### Table 1 Characteristics at baseline (at enrolment in the cohort) according to pregnancy status in the course of follow-up

| Characteristics at baseline | Women without pregnancy in the course of follow-up | Pregnant women who reintegrated the cohort following pregnancy | Pregnant women who did not reintegrate the cohort following pregnancy | *p*-value |
|-----------------------------|---------------------------------------------------|--------------------------------------------------------------|------------------------------------------------------------------|----------|
|                             | N = 2353                                          | N = 29                                                       | N = 93                                                           |          |
| Age (mean, SD)              | 32.7 (8.8)                                        | 26.7 (6.1)                                                  | 27.2 (5.4)                                                       | 0.609    |
| Age (median, IQR)           | 32.0 (26.0-39.0)                                  | 26.0 (21.0-31.5)                                            | 27.0 (22.3-31.0)                                                |          |
| Cytology                    |                                                   |                                                              |                                                                  |          |
| Negative                    | 96.2                                              | 86.2                                                        | 90.0                                                             |          |
| ASC/AGUS                    | 1.7                                               | 0.0                                                         | 5.0                                                              | 0.221    |
| LSIL                        | 1.2                                               | 6.9                                                         | 1.3                                                              |          |
| HSIL                        | 0.7                                               | 6.9                                                         | 3.8                                                              |          |
| HPV status                  |                                                   |                                                              |                                                                  |          |
| Neg                         | 82.6                                              | 72.4                                                        | 77.5                                                             |          |
| LR-HPV only                 | 6.4                                               | 10.3                                                        | 5.0                                                              | 0.600    |
| Any-HR                      | 10.1                                              | 17.2                                                        | 16.3                                                             |          |
| Ethnicity                   |                                                   |                                                              |                                                                  |          |
| White                       | 64.9                                              | 55.2                                                        | 53.8                                                             |          |
| Nonwhite                    | 35.1                                              | 44.8                                                        | 46.3                                                             | 0.895    |
| Marital status              |                                                   |                                                              |                                                                  |          |
| Single                      | 10.3                                              | 6.9                                                         | 10.0                                                             | 0.148    |
| Married                     | 48.3                                              | 48.3                                                        | 35.0                                                             |          |
| Unmarried, but living with partner |                         | 33.1                                                        | 37.9                                                             | 53.8     |
| Quartiles of income         |                                                   |                                                              |                                                                  |          |
| 1 (lowest)                  | 24.8                                              | 37.9                                                        | 27.9                                                             |          |
| 2                           | 24.8                                              | 17.2                                                        | 25.3                                                             | 0.069    |
| 3                           | 25.3                                              | 34.5                                                        | 17.7                                                             |          |
| 4 (highest)                 | 25.1                                              | 10.3                                                        | 29.1                                                             |          |
| Age at first intercourse    |                                                   |                                                              |                                                                  |          |
| 20+                         | 26.4                                              | 13.8                                                        | 12.5                                                             |          |
| 18-19                       | 21.2                                              | 0.0                                                         | 25.0                                                             | 0.324    |
| 16-17                       | 25.6                                              | 37.9                                                        | 26.3                                                             |          |
| <=15                        | 26.9                                              | 48.3                                                        | 36.3                                                             |          |
| Previous pregnancy          |                                                   |                                                              |                                                                  |          |
| 0-1                         | 16.9                                              | 24.1                                                        | 20.0                                                             |          |
| 2-3                         | 42.8                                              | 24.1                                                        | 42.5                                                             |          |
| 4-6                         | 30.1                                              | 44.8                                                        | 27.5                                                             | 0.231    |
| 7+                          | 10.2                                              | 6.9                                                         | 10.0                                                             |          |
| Lifetime number of sexual partners |                         |                                                              |                                                                  |          |
| 0-1                         | 44.3                                              | 44.8                                                        | 41.3                                                             |          |
| 2-3                         | 34.7                                              | 31.0                                                        | 40.0                                                             |          |
| 4+                          | 20.9                                              | 24.1                                                        | 18.8                                                             | 0.662    |
| Ever had PAP cytology before |                                                   |                                                              |                                                                  |          |
| No                          | 50.0                                              | 3.5                                                         | 12.5                                                             |          |
| Yes                         | 95.0                                              | 96.6                                                        | 87.5                                                             | 0.166    |
| Smoking                     |                                                   |                                                              |                                                                  |          |
| Never                       | 47.6                                              | 51.7                                                        | 40.0                                                             |          |
| Current                     | 34.9                                              | 27.6                                                        | 43.8                                                             | 0.312    |
| Former                      | 17.4                                              | 20.7                                                        | 16.3                                                             |          |

*P*-value to test the difference between pregnant women who reintegrated and those who did not reintegrate the cohort following pregnancy. P-values estimated with Pearson’s chi-squared for categorical variables and student t-test for continuous variables.

Total may not sum 100% due to missing data. SD standard deviation, IQR interquartile range.
suggest, that careful monitoring of HPV positive women in the post-partum period may be warranted.

It is not clear however, whether or not the risk of progression of HPV infection to cervical neoplasia (preinvasive and invasive cancer) is higher when detected during pregnancy. Studies on the progression of biopsy proven cervical neoplasia during pregnancy are rare, since biopsies tend to be avoided during pregnancy. When Pap results are used to estimate risk, reports provide a wide range of estimates: 10–70 % of cytological abnormalities found during pregnancy regress, 25–89 % persist without progression and 3–30 % progress [33–46]. Studies on evolution of HSIL during pregnancy and the post-partum period show a range of progression to micro-invasive carcinoma from 0 to 14.2 % and a very low risk of progression to frankly invasive cancer (0.1 %) (reviewed in Serati et al., [44]).

This study has limitations. It is possible that residual confounding may explain our findings. For example, lack of control for women’s partners’ sexual behaviour could create confounding if pregnancy is associated with a higher likelihood of partners’ extra-conjugal sexual relationships. However, this potential confounding bias is unlikely to have occurred, as no association was found for HPV infection or LSIL. We also used cytology and not histology results in this analysis. However, Morimura et al. (2002) [31] has shown that the accuracy of cytology Pap testing is similar between pregnant and non-pregnant women. As this potential information bias is non-differential, it would have only underestimated the relative risk we found. Finally, most of the women in our cohort already had their children at the time of recruitment and only a small number of women experienced a pregnancy within the cohort. Moreover, a criterion for recruitment in our cohort was not being currently pregnant and no intention of becoming pregnant during the first year of follow-up, which reduced the number of pregnancies in the cohort and the number of women who reentered the cohort after birth.

Table 2 Crude and adjusted odds ratios (ORs) for the association between HPV detection or squamous intraepithelial lesion (SIL) and pregnancy

| Outcome                        | Post pregnancies observation visits (n) | Crude OR | 95 % CI       | Adjusted ORa | 95 % CI       |
|--------------------------------|----------------------------------------|----------|---------------|---------------|---------------|
|                                | No pregnancy                           | Pregnancy|               |               |               |
| HPVb                           | HPV (−/+                               | 19948/3787 | 23/6          | 0.85          | (0.33–2.14)   | 0.80          | (0.31–2.07)   |
| Any HR-HPV                     | 19948/2281                               | 23/3      | 0.80          | (0.24–2.65)   | 0.80          | (0.24–2.71)   |
| LR-HPV only                    | 19948/1506                              | 23/3      | 1.15          | (0.31–4.23)   | 1.18          | (0.34–4.15)   |
| Speciesb                       | 3                                       | 19948/638 | 23/1          | 1.49          | (0.26–8.50)   | 1.32          | (0.22–7.97)   |
|                               | 5                                       | 19948/343 | 23/1          | 2.32          | (0.35–15.23)  | 1.86          | (0.28–12.15)  |
|                               | 6                                       | 19948/505 | 23/1          | 1.06          | (0.11–9.83)   | 0.91          | (0.10–8.12)   |
|                               | 7                                       | 19948/645 | 23/1          | 1.23          | (0.20–7.60)   | 0.98          | (0.15–6.24)   |
|                               | 9                                       | 19948/1407 | 23/1        | 0.48          | (0.07–3.21)   | 0.43          | (0.07–2.59)   |
|                               | 10                                      | 19948/303 | 23/1          | 1.26          | (0.09–17.40)  | 1.29          | (0.13–12.93)  |
| Group                          | 1 (species-1/8/10/13)                   | 19948/399 | 23/1          | 0.93          | (0.64–13.53)  | 1.05          | (0.10–10.53)  |
|                               | 2 (species-5/6/7/9/11)                  | 19948/2566 | 23/4       | 0.87          | (0.29–2.56)   | 0.77          | (0.27–2.21)   |
|                               | 3 (species-2/3/4/15)                    | 19948/716 | 23/1          | 1.41          | (0.26–7.64)   | 1.25          | (0.21–7.29)   |
| Squamous intraepithelial lesions (SILs) | SIL (−/+)                             | 23845/258 | 28/0        | –             | –             | –             | –             |
| Low-grade SILs                | 23845/76                               | 28/1      | 7.77          | (0.93–65.08)  | 8.75          | (1.00–77.03)  |
| Any-grade SILs                | 23845/334                              | 28/1      | 0.91          | (0.05–18.27)  | 0.84          | (0.46–15.33)  |

aExcludes women-visits for which HPV testing was invalid or missing
bAdjustment for empirical confounders was done using a 5 % Change-in-Estimate Method (variables that changed the estimates by +/− 5 % were included in the model) considering the following variables as a potential confounder: age at enrolment (linear), race (white, non-White), marital status (single, married, widowed, separated, unmarried but living with partner), income (quartiles of income), smoking (never, current, former), age at first sexual intercourse (≤15, 16–17, 18–19, 20 +), number of previous pregnancies (0–1, 2–3, 4–6, 7+), Pap testing before enrollment in the cohort (yes, no), and lifetime number of sexual partners (0–1, 2–3, 4 +). Adjustment for HPV status (negative, LR-HPV only, any HR-HPV) was considered for the analysis of SILs. Confounding variables added to the multivariate models for HPVs (variables that changed the OR for the relation between pregnancy and HPV status by +/− 5 %) were: number of previous pregnancies, age at first sexual intercourse, age, race and smoking status. For SILs, confounding variables added to the multivariate models were: HPV status, age, smoking, race, age at first sexual intercourse, number of previous pregnancies and Pap testing before entering the cohort.
One of the strengths of our study was the use of a longitudinal design approach including prospective collection of data before and after pregnancy. This limits the potential for bias that would have occurred if pregnant women were more likely to be screened compared to non-pregnant women because all pregnant women in our study were similarly followed-up in the cohort prior to becoming pregnant. We also applied a conservative control for confounding including sexual behaviour and variables that were different between pregnant and non-pregnant women such as age.

Conclusions
In conclusion, we found no association between pregnancy and HPV infection and cervical lesions but admittedly, our cohort included a limited number of pregnant women. A single SIL case (an HSIL) occurred post-partum which calls for caution in interpretation.

Competing interests
HT has served as a paid consultant for and has received travel assistance from GlaxoSmithKline Biologicals, Merck, and Gilead Science. MHM has received consulting and lecture fees from Merck, Pfizer, Roche and GlaxoSmithKline. EF has received occasional lecture or consultation fees from Merck, GlaxoSmithKline, Roche and Gen-Probe. AF is a paid consultant for Merck, BD, Roche Diagnostic Systems, Hologic (GenProbe), Cepheid and Inovio. LV has received occasional lecture or consultation fees from Merck, Sharp and Dohme.

Authors’ contribution
All authors of this research paper have directly contributed to the conception and design (ELF, LLV), or acquisition of data (MLB, LG, AF), or analysis and interpretation (HT, MHM, AF, LLV, ELF) of the study. HT, MHM and ELF wrote the first draft of the manuscript. All authors have subsequently read, revised, and approved the version that is now being submitted.

Acknowledgments
Ludwig–McGill cohort study team members: affiliated with the Ludwig Institute for Cancer Research in Sao Paulo, Brazil: Maria Luiza Baggio, Lionice Galian, João Simão Sobrinho, José Carlos Mann Prado, Silvaniede Ferreira, Laura Termini, Maria Cecilia Costa, Romulo Miyamura, Andrea Trevisan, Patricia Thomann, João Candeias, Laura Sichero, Paula Rahal, Antonio Ruiz, Jane Kaiona, Monica Santos, Patricia Siao, Paulo Maciag, Tatiana Rabachini, Luisa Villa (Co-Principal Investigator). Affiliated with McGill University in Montreal, Canada: Marie-Claude Rousseau, Salasheeddin Mahmud, Nicolas Schlecht, Helen Trottier, Alex Ferenczy, Thomas Rohan, Myriam Chevarie-Davis, Joseph Tota, Agnihotram Ramanakumar, Eliane Duarte, Sophie Kulaga, Juliette Robitaille, Robert Platt, Eduardo Franco (Principal Investigator). We are grateful to Silvaniede Ferreira and Rache Hessel for study coordination and to Romulo Miyamura, João Simão Sobrinho, José Carlos Mann Prado and Maria Cecilia Costa for DNA testing and typing. This study was supported by an intramural grant from the Ludwig Institute for Cancer Research to LLV and ELF and by grants from the U.S. National Cancer Institute (CA70250) and the Canadian Institutes of Health Research (MA13647) to ELF. MHM holds a salary award (chercheur-boursier) from the Fonds de la recherche du Québec en santé (FRQ-Sciences). HT holds a salary award (MA13647) to ELF. MHM holds a salary award (chercheur-boursier) from the Canadian Institutes of Health Research. We are grateful to Silvaniede Ferreira and Rache Hessel for study coordination and to Romulo Miyamura, João Simão Sobrinho, José Carlos Mann Prado and Maria Cecilia Costa for DNA testing and typing. This study was supported by an intramural grant from the Ludwig Institute for Cancer Research to LLV and ELF and by grants from the U.S. National Cancer Institute (CA70250) and the Canadian Institutes of Health Research (MA13647) to ELF. MHM holds a salary award (chercheur-boursier) from the Fonds de la recherche du Québec en santé (FRQ-S). HT holds a salary award (chercheur-boursier) from the FRQ-S and from the Canadian Institutes of Health Research (CIHR).

Author details
1Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada. 2Department of Social and Preventive Medicine, Université de Montréal, Montreal, Canada. 3Sainte-Justine Hospital Research Center, Department of Social and Preventive Medicine, Université de Montréal, 3175 Côte Sainte-Catherine, Room A-830, Montreal, QC, H3T 1C5, Canada. 4Department of Obstetrics and Gynecology, Université de Montréal and CRCHUM, Montreal, Canada. 5Ludwig Institute for Cancer Research, São Paulo, Brazil. 6Department of Pathology, McGill University and Jewish General Hospital, Montreal, Canada. 7Department of Radiology and Oncology, School of Medicine, Université de São Paulo, São Paulo, Brazil.

Received: 11 February 2015 Accepted: 2 October 2015
Published online: 07 October 2015

References
1. de Sanjosé S, Quint WG, Alemayhu L, Geraets DT, Klauetermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey. Lancet Oncol. 2010;11:1048–56.
2. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus (HPV) infection and HPV-associated diseases. Public Health Genomics. 2009;12(5–6):291–307.
3. Trottier H, Franco EL. Human papillomavirus (HPV) and cervical cancer: burden and epidemiology. Am J Manag Care. 2006;12(17 Suppl):S462–72.
4. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:S1–15.
5. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith J, et al. Bosch FX, International Agency for Research on Cancer. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359(9312):1093–101.
6. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erker M, Matalashevski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999;6:223–33.
7. Broder S. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses—Report of the 1991 Bethesda Workshop. JAMA. 1992;267:1892.
8. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265:472–7.
9. Gravitt PE, Peyton CL, Alesi TG, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357–61.
10. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses, vol. 90. Lyon, France: International Agency for Research on Cancer (IARC); 2007.
11. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:1851–67.
12. de Villiers EM, Fauquet C, Bernard HU, Broker TR, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27.
13. Schiffman M, Herrero R, Desale M, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76–84.
14. Nair HB, Luthra R, Karna N, Liu YG, Flowers L, Evans D, et al. Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res. 2005;65:11164–73.
15. Delvenne P, Herman L, Kholod N, Caberg JH, Herfs M, Boniver J, et al. Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Mol Cell Endocrinol. 2007;264:1–5.
16. Scully Jr WC, McGinn JD. Recurrent respiratory papillomatosis in pregnancy: a case of emergent airway management. Ear Nose Throat J. 2008;87(6):E8–11.
17. Sethi S, Muller M, Schneider A, Blettner M, Smith E, Turek L, et al. Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women. Am J Obstet Gynecol. 1998;178:350–4.
18. Smith EM, Johnson SR, Jiang D, Zaleski S, Lynch CF, Brundage S, et al. The association between pregnancy and human papillomavirus virus prevalence. Cancer Detect Prev. 1995;19:397–402.
19. Soares VR, Neminen P, Aho M, Vesterinen E, Vaheri A, Paavonen J. Human papillomavirus DNA in unscreened pregnant and non-pregnant women. Int J STD AIDS. 1990;1:276–8.
20. De Roda Husman AM, Walboomers JM, Hopman S, Bleker OP, Helmerhorst TM, Rozendaal L, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR. The age-related pattern. J Med Virol. 1995;46:69–102.
21. Chang-Claude J, Schneider A, Smith E, Blettner M, Wahrendorf J, Turek L. Longitudinal study of the effects of pregnancy and other factors on detection of HPV. Gynecol Oncol. 1996;60:335–62.
22. Tenti P, Zappatore R, Migliora P, Spinillo A, Maccarini U, De Benedittis M, et al. Latent human papillomavirus infection in pregnant women at term: A case– control study. J Infect Dis. 1997;176:277–80.
23. Chan PK, Chang AR, Tam WH, Cheung JL, Cheng AF. Prevalence and genotype distribution of cervical human papillomavirus infection: Comparison between pregnant women and non-pregnant controls. J Med Virol. 2002;67:583–8.
24. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozenaal L, Bezemer PD, Voorhorst FJ, et al. High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer. 2002;87:75–80.
25. Minkhoff H, Shen X, Watts DH, Leighty R, Hershov R, Palefsky J, et al. Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women. Obstet Gynecol. 2006;108:953–60.
26. Banura C, Franceschi S, van Doorn Li, Anslan A, Kletter B, Wabwire-Mangen F, et al. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer. 2008;123(9):2180–7.
27. Schmeink CE, Melchers WJ, Hendriks JC, Quint WG, Massuger LF, Bekkers RL. Human papillomavirus detection in pregnant women: a prospective matched cohort study. J Womens Health (Larchmt). 2012;21(12):1295–301.
28. Fife KH, Katz BP, Roueh J, Handy VD, Brown DR, Hansell R. Cancer-associated human papillomavirus types are selectively increased in the cervix of women in the first trimester of pregnancy. Am J Obstet Gynecol. 1996;174:1487–93.
29. Gopalkrishna V, Murthy NS, Sharma JK, Roy M, Das DK, Luthra UK, et al. Increased human papillomavirus infection with the increasing number of pregnancies in Indian women. J Infect Dis. 1995;171:254–5.
30. Hernandez-Giron C, Smith JS, Lorincz A, Lazcano E, Hernandez-Avila M, Salmeron J. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis. 2005;32:513–18.
31. Morimura Y, Fujimori K, Soeda S, Hashimoto T, Takano Y, Yamada H, et al. Cervical cytology during pregnancy—comparison with non-pregnant women and management of pregnant women with abnormal cytology. Fukushima J Med Sci. 2002;48(1):27–37.
32. Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013;108(1):234–9.
33. Ahdoott D, Van Nostrand KM, Nguyen NJ, Tewari DS, Kurasaki T, DiSaia PJ, et al. The effect of route of delivery on regression of abnormal cervical cytologic findings in the postpartum period. Am J Obstet Gynecol. 1998;178:1116–20.
34. Palle C, Bangsboll S, Andreassen B. Cervical intraepithelial neoplasia in pregnancy. Acta Obstet Gynecol Scand. 2000;79:306–10.
35. Vlahos G, Rodalakis A, Diakomanolis E, Stefanidis K, Haidopoulos D, Abela K, et al. Conservative management of cervical intraepithelial neoplasia (CIN2–3) in pregnant women. Gynecol Obstet Invest. 2002;54:78–81.
36. Coppola A, Sorsky J, Casper R, Anderson B, Buller RE. The clinical course of cervical carcinoma in situ diagnosed during pregnancy. Gynecol Oncol. 1997;67:162–5.
37. Baldauf JJ, Dreyfus M, Ritter J, Philippe E. Colposcopy and directed biopsy reliability during pregnancy: a cohort study. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):31–6.
38. Yost N, Santosio JT, McIntire D, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol. 1999;93:359–62.
39. Paraskevaidis E, Koliopoulos G, Kalantaridou S, Pappa L, Navrozoglou I, Zikopoulos K, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. Eur J Obstet Gynecol Reprod Biol. 2002;104:67–9.
40. Douvier S, Filippuzzi I, Sagot P. Management of cervical intra-epithelial neoplasia during pregnancy. Gynecol Obstet Fertil. 2003;31(1):851–5.
41. Siddiqui G, Kurzel RB, Lampley EC, Kang HS, Blankstein J. Cervical dysplasia in pregnancy: progression versus regression post-partum. Int J Fertil Womens Med. 2001;46(5):278–80.
42. Kaplan KL, Dainty LA, Dolinsky B, Rose GS, Carlson J, McHale M, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer. 2004;102:228–32.
43. Frega A, Scirpa P, Corosu R, Verriolo M, Scariglia ML, Primieri MR, et al. Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. Anticancer Res. 2007;27(4C):2743–6.
44. Serati M, Uccella S, Laterza RM, Salvatore S, Beretta P, Riva C, et al. Natural history of cervical intraepithelial neoplasia during pregnancy. Acta Obstet Gynecol Scand. 2008;87:1296–300.
45. Cubo-Abert M, Centeno-Medialdea C, Franco-Zabala P, Merced-Vázquez C, Castellvi J, García A, et al. Risk factors for progression or persistence of squamous intraepithelial lesions diagnosed during pregnancy. J Low Genit Tract Dis. 2012;16(1):34–8.
46. Coppolillo EF, DE Ruda Vega HM, Brizuela J, Eliseit MC, Barata A, Perazzi BE. High-grade cervical neoplasia during pregnancy: diagnosis, management and postpartum findings. Acta Obstet Gynecol Scand. 2013;92(3):293–7.